New York: Pfizer has announced that it has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.

The lawsuit asserts that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its dominant market position in GLP-1s by capturing and killing a nascent American competitor before it gains the support of Pfizer.

The lawsuit alleges that Novo Nordisk ’s proposed transaction violates Section 7 of the Clayton Act because of the anticompetitive effects it would have in the GLP-1 drug markets to the detriment of millions of Americans who suffer from obesity, diabetes, and other metabolic conditions, that it constitutes an anticompet

See Full Page